Can penicillamine cause loose wrinkled skin, and does switching drugs help?
Penicillamine can cause two distinct skin conditions — cutis laxa and elastosis perforans serpiginosa — that are real side effects; switching to trientine often stops progression, but reversal of existing changes is partial at best.
If you have noticed loose, saggy, or wrinkled skin developing around your neck, armpits, or other body folds while taking penicillamine, you are not imagining things. This is a recognized skin complication of long-term penicillamine use, and it has a name: penicillamine-induced cutis laxa (sometimes alongside a related but distinct condition called elastosis perforans serpiginosa, or EPS). Both conditions involve damage to the elastic fibers in skin. The encouraging news is that switching to a different copper-lowering drug usually stops further progression. The less encouraging news is that existing skin changes rarely reverse completely — though some improvement is possible over time.
What exactly is happening to your skin
Elastic fibers give skin its ability to snap back into shape. Penicillamine interferes with cross-linking of both elastin and collagen, two structural proteins that keep skin firm.1 With years of use, this can produce two patterns:
Cutis laxa (acquired): The skin literally loses its elasticity and hangs loosely, especially in areas where skin naturally folds — neck, underarms, groin, eyelids. It does not spring back when pinched. In severe cases it can give an appearance of premature aging far beyond the patient’s actual age.
Elastosis perforans serpiginosa (EPS): This is different in character. It produces small, keratotic (rough, bumpy) papules arranged in a ring or serpentine pattern, usually on the neck and upper arms. Under a microscope, abnormal elastic tissue can be seen being extruded through the skin.2 EPS can itch and may be mistaken for a fungal rash.
The two conditions can coexist, as documented in published case series.3 Skin biopsy is the definitive way to distinguish them and rule out other causes, and your dermatologist may recommend one.
Both conditions are uncommon but have been reported since the 1970s in Wilson disease patients on long-term penicillamine.4 A 2024 case report confirmed that even with modern dosing protocols, penicillamine-induced cutis laxa can develop after years of treatment.5
Does switching away from penicillamine help?
The clear answer is: it stops the damage from getting worse. Whether existing changes reverse depends on how long you have been on penicillamine and how much elastin loss has already occurred.
Stopping penicillamine removes the trigger, but elastic fibers that have already been destroyed do not regenerate quickly — if at all. Most published cases report stabilization of the skin condition after switching, with only modest cosmetic improvement over months to years.1 Some patients describe the skin feeling slightly less lax over time, but returning to pre-penicillamine appearance is not a realistic expectation for established cutis laxa.
For EPS specifically, case reports describe gradual improvement after switching drugs, though the keratotic papules may take a year or more to fade and may not disappear entirely.3
The main alternatives if you need to remain on a copper-chelating drug are:
| Alternative | Notes |
|---|---|
| Trientine | The most common switch; also a chelator but acts through a different mechanism and does not carry the same elastin-disrupting effect |
| Zinc | A non-chelating maintenance option for patients who are already stable; does not damage connective tissue |
| Tetrathiomolybdate | Still under clinical investigation in some centres; different mechanism again |
The decision about which drug to switch to — and whether your current control of copper is good enough to drop to a milder agent like zinc — is one your Wilson specialist needs to guide based on your liver function, copper indices, and how long you have been stable.6
What to tell your doctor
Some practical points for your next appointment:
- Describe when the skin changes started relative to when you began penicillamine, and whether they have been progressing.
- Ask for a dermatology referral. A dermatologist can biopsy the skin to confirm the diagnosis, distinguish cutis laxa from EPS (or both), and advise on any local treatments for EPS lesions (retinoids and imiquimod have been used with some success in EPS, though evidence is limited).
- Ask your Wilson specialist to review your penicillamine dose. Sometimes dose reduction alone, if copper control allows it, can slow progression without requiring a full switch.
- Ask about monitoring skin over time once any switch is made, so you have documentation of whether things stabilize or improve.
One thing worth knowing: cutis laxa induced by penicillamine is not the same as congenital cutis laxa (a genetic condition present from birth). Penicillamine can also rarely cause cutis laxa in babies born to women who took it during pregnancy — this is a separate concern covered in our pregnancy page.
What about cosmetic correction?
Plastic or reconstructive surgery for excess skin can be considered once the underlying cause has been removed and the skin changes have stabilized — but this is a purely elective and personal decision, and surgical teams will want confirmation that you are no longer on penicillamine. There are no drug or cream-based treatments proven to rebuild lost elastic tissue.
The most important step right now is getting the diagnosis confirmed and having an informed conversation with your Wilson specialist about whether the drug that has served you well so far is still the best option going forward. Many patients switch to trientine with good copper control and no further skin deterioration.
This page is patient education, not medical advice. Skin changes from penicillamine should be assessed by both your Wilson specialist and a dermatologist. Do not stop or change your Wilson disease medication without medical guidance — maintaining copper control is always the priority.
References
-
Hill, V. A., H. S. Seymour, and R. Voller. “Penicillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson’s disease.” British Journal of Dermatology 142, no. 3 (2000): 560–561. https://doi.org/10.1046/j.1365-2133.2000.03379.x. ↩↩
-
Pass, F., C. M. Goldfischer, and S. Sternlieb. “Elastosis perforans serpiginosa during penicillamine therapy for Wilson disease.” Archives of Dermatology 108, no. 5 (1973): 713–715. https://doi.org/10.1001/archderm.1973.01620260061026. ↩
-
Ma, Zhuang, et al. “Coexisting elastosis perforans serpiginosa and acquired cutis laxa following long-term penicillamine therapy.” Skin Health and Disease (2025). https://doi.org/10.1093/skinhd/vzaf060. ↩↩
-
Walshe, J. M. “Congenital cutis laxa and maternal d-penicillamine.” The Lancet 2, no. 8137 (1979): 478. https://doi.org/10.1016/s0140-6736(79)90019-9. ↩
-
Routsi, E., et al. “Penicillamine-Induced Localised Cutis Laxa in a Patient with Wilson Disease: A Case Report.” Mediterranean Journal of Rheumatology (2024). https://doi.org/10.31138/mjr.280223.pil. ↩
-
Schilsky, Michael L., Eve A. Roberts, Jill Bronstein, et al. “A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance from the American Association for the Study of Liver Diseases.” Hepatology 77, no. 4 (2022): 1428–1455. https://doi.org/10.1002/hep.32801. ↩
-
Członkowska, Anna, Tomasz Litwin, Piotr Dusek, Petr Ferenci, et al. “Wilson disease.” Nature Reviews Disease Primers 4 (2018): 21. https://doi.org/10.1038/s41572-018-0024-5. ↩
-
EASL Clinical Practice Guidelines. “Wilson’s disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. ↩
-
Roberts, Eve A. “Trientine for Wilson Disease: Contemporary Issues.” In Wilson Disease, edited by Michael L. Schilsky. New York: Elsevier, 2019. https://doi.org/10.1016/b978-0-12-811077-5.00017-7. ↩
Queste informazioni sono per i pazienti e non costituiscono un consiglio medico. Consulta sempre il tuo team clinico per le decisioni che riguardano la tua cura.